GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Float Percentage Of Total Shares Outstanding

VOQP (VioQuest Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 0.00% (As of Sep. 25, 2024)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, VioQuest Pharmaceuticals's float shares is 0.00 Mil. VioQuest Pharmaceuticals's total shares outstanding is 5.46 Mil. VioQuest Pharmaceuticals's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, VioQuest Pharmaceuticals's Insider Ownership is 5.38%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, VioQuest Pharmaceuticals's Institutional Ownership is 0.00%.


VioQuest Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

VioQuest Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/5.46
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals Headlines

No Headlines